Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Optimi Health ( (TSE:OPTI) ) has issued an announcement.
Optimi Health has been chosen to supply MDMA capsules for a clinical trial in Israel, sponsored by Sheba Medical Center, aimed at treating trauma-related PTSD. The trial, part of MAPS Israel’s Healing October 7th initiative, will assess the effectiveness of group versus individual MDMA-assisted therapy for 168 patients. This collaboration marks a significant step for Optimi’s MDMA product, potentially expanding access to PTSD treatment and enhancing the company’s position in the psychedelic-assisted therapy industry.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Spark’s Take on TSE:OPTI Stock
According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.
Optimi Health’s overall score is primarily impacted by its financial performance, which shows potential but is hindered by persistent losses and cash flow challenges. Technical analysis provides some positive momentum signals, but valuation concerns due to negative earnings weigh heavily on the score.
To see Spark’s full report on TSE:OPTI stock, click here.
More about Optimi Health
Optimi Health Corp. is a Canadian manufacturer specializing in pharmaceutical-grade psychedelics, including MDMA and naturally derived psilocybin. The company focuses on supplying high-quality GMP medicines for modern clinical research.
Average Trading Volume: 129,610
Technical Sentiment Signal: Buy
Current Market Cap: C$33.82M
See more data about OPTI stock on TipRanks’ Stock Analysis page.